Evidence map›Paper›PMID 32071892›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2020

At-line high throughput site-specific glycan profiling using targeted mass spectrometry.

Bertie Chi, Christel Veyssier, Toyin Kasali, Faisal Uddin, Christopher A Sellick

Abstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bertie ChiMedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.
Christel VeyssierMedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.
Toyin KasaliMedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.
Faisal UddinMedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.
Christopher A SellickMedImmune, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein post-translational modification (PTM) plays an important role in many biological processes; of which glycosylation is arguably one of the most complex and diverse modifications and is crucial for the safety and efficacy of biotherapeutic proteins. Mass spectrometric characterization of protein glycosylation is well established with clear advantages and disadvantages; on one hand it is precise and information-rich, as well as being relative inexpensive in terms of the reagents and consumables despite the instrumentation cost and, depending on the method, can give site specific information; on the other hand it generally suffers from low throughput, restriction to largely purified samples and is less quantitative, especially for sialylated glycan species. Here, we describe a high throughput, site-specific, targeted mass spectrometric peptide mapping approach to quickly screen/rank candidate production cell lines and culture conditions that give favourable glycosylation profiles directly from conditioned culture media for an Fc-fusion protein. The methodology is fully compatible with automation and combines the speed of 'top-down' mass spectrometry with the site-specific information of 'bottom-up' mass spectrometry. In addition, this strategy can be used for multi-attribute product quality screening/monitoring as an integral part of cell line selection and process development.

Indexed as

2-AB, 2-aminobenzamide labelled UPLC glycan analysisCell line selectionCM, conditioned mediaDoE, design of experimentESI, electrospray ionizationGlycan profilingGlycosylationPKPD, pharmacokinetic pharmacodynamicPTM, post-translation modificationQBD, quality by designTargeted mass spectrometryTQ-MS, triple quadrupole mass spectrometry

Identifiers

PMID32071892
PMCPMC7016254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.